Literature DB >> 27141376

Spatial distribution of B cells predicts prognosis in human pancreatic adenocarcinoma.

Giovanni Francesco Castino1, Nina Cortese1, Giovanni Capretti2, Simone Serio3, Giuseppe Di Caro1, Rossana Mineri4, Elena Magrini1, Fabio Grizzi1, Paola Cappello5, Francesco Novelli5, Paola Spaggiari6, Massimo Roncalli6, Cristina Ridolfi2, Francesca Gavazzi2, Alessandro Zerbi2, Paola Allavena1, Federica Marchesi7.   

Abstract

B-cell responses are emerging as critical regulators of cancer progression. In this study, we investigated the role of B lymphocytes in the microenvironment of human pancreatic ductal adenocarcinoma (PDAC), in a retrospective consecutive series of 104 PDAC patients and in PDAC preclinical models. Immunohistochemical analysis revealed that B cells occupy two histologically distinct compartments in human PDAC, either scatteringly infiltrating (CD20-TILs), or organized in tertiary lymphoid tissue (CD20-TLT). Only when retained within TLT, high density of B cells predicted longer survival (median survival 16.9 mo CD20-TLThi vs. 10.7 mo CD20-TLTlo; p = 0.0085). Presence of B cells within TLT associated to a germinal center (GC) immune signature, correlated with CD8-TIL infiltration, and empowered their favorable prognostic value. Immunotherapeutic vaccination of spontaneously developing PDAC (KrasG12D-Pdx1-Cre) mice with α-enolase (ENO1) induced formation of TLT with active GCs and correlated with increased recruitment of T lymphocytes, suggesting induction of TLT as a strategy to favor mobilization of immune cells in PDAC. In contrast, in an implanted tumor model devoid of TLT, depletion of B cells with an anti-CD20 antibody reinstated an antitumor immune response. Our results highlight B cells as an essential element of the microenvironment of PDAC and identify their spatial organization as a key regulator of their antitumor function. A mindfully evaluation of B cells in human PDAC could represent a powerful prognostic tool to identify patients with distinct clinical behaviors and responses to immunotherapeutic strategies.

Entities:  

Keywords:  B cells; biomarkers; immunotherapy; pancreatic adenocarcinoma (PDAC); tertiary lymphoid tissue

Year:  2015        PMID: 27141376      PMCID: PMC4839336          DOI: 10.1080/2162402X.2015.1085147

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  52 in total

1.  Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration.

Authors:  Douglas G Altman; Lisa M McShane; Willi Sauerbrei; Sheila E Taube
Journal:  PLoS Med       Date:  2012-05-29       Impact factor: 11.069

2.  Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures.

Authors:  Marie-Caroline Dieu-Nosjean; Martine Antoine; Claire Danel; Didier Heudes; Marie Wislez; Virginie Poulot; Nathalie Rabbe; Ludivine Laurans; Eric Tartour; Luc de Chaisemartin; Serge Lebecque; Wolf-Herman Fridman; Jacques Cadranel
Journal:  J Clin Oncol       Date:  2008-09-20       Impact factor: 44.544

3.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Authors:  Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux
Journal:  N Engl J Med       Date:  2011-05-12       Impact factor: 91.245

Review 4.  Effector and regulatory B cells: modulators of CD4+ T cell immunity.

Authors:  Frances E Lund; Troy D Randall
Journal:  Nat Rev Immunol       Date:  2010-03-12       Impact factor: 53.106

Review 5.  Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity.

Authors:  Suzanne L Topalian; Charles G Drake; Drew M Pardoll
Journal:  Curr Opin Immunol       Date:  2012-01-09       Impact factor: 7.486

Review 6.  CD20+ B cells: the other tumor-infiltrating lymphocytes.

Authors:  Brad H Nelson
Journal:  J Immunol       Date:  2010-11-01       Impact factor: 5.422

7.  Cluster analysis and display of genome-wide expression patterns.

Authors:  M B Eisen; P T Spellman; P O Brown; D Botstein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-08       Impact factor: 11.205

8.  Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells.

Authors:  Jérémy Goc; Claire Germain; Thi Kim Duy Vo-Bourgais; Audrey Lupo; Christophe Klein; Samantha Knockaert; Luc de Chaisemartin; Hanane Ouakrim; Etienne Becht; Marco Alifano; Pierre Validire; Romain Remark; Scott A Hammond; Isabelle Cremer; Diane Damotte; Wolf-Herman Fridman; Catherine Sautès-Fridman; Marie-Caroline Dieu-Nosjean
Journal:  Cancer Res       Date:  2013-12-23       Impact factor: 12.701

9.  Depletion of normal B cells with rituximab as an adjunct to IL-2 therapy for renal cell carcinoma and melanoma.

Authors:  M Aklilu; W M Stadler; M Markiewicz; N J Vogelzang; M Mahowald; M Johnson; T F Gajewski
Journal:  Ann Oncol       Date:  2004-07       Impact factor: 32.976

10.  Dynamics of the immune reaction to pancreatic cancer from inception to invasion.

Authors:  Carolyn E Clark; Sunil R Hingorani; Rosemarie Mick; Chelsea Combs; David A Tuveson; Robert H Vonderheide
Journal:  Cancer Res       Date:  2007-10-01       Impact factor: 12.701

View more
  64 in total

Review 1.  B cells, plasma cells and antibody repertoires in the tumour microenvironment.

Authors:  George V Sharonov; Ekaterina O Serebrovskaya; Diana V Yuzhakova; Olga V Britanova; Dmitriy M Chudakov
Journal:  Nat Rev Immunol       Date:  2020-01-27       Impact factor: 53.106

2.  Tumor infiltrating B-cells signal functional humoral immune responses in breast cancer.

Authors:  Soizic Garaud; Laurence Buisseret; Cinzia Solinas; Chunyan Gu-Trantien; Alexandre de Wind; Gert Van den Eynden; Celine Naveaux; Jean-Nicolas Lodewyckx; Anaïs Boisson; Hughes Duvillier; Ligia Craciun; Lieveke Ameye; Isabelle Veys; Marianne Paesmans; Denis Larsimont; Martine Piccart-Gebhart; Karen Willard-Gallo
Journal:  JCI Insight       Date:  2019-08-13

Review 3.  Trial watch: Immune checkpoint blockers for cancer therapy.

Authors:  Claire Vanpouille-Box; Claire Lhuillier; Lucillia Bezu; Fernando Aranda; Takahiro Yamazaki; Oliver Kepp; Jitka Fucikova; Radek Spisek; Sandra Demaria; Silvia C Formenti; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-08-31       Impact factor: 8.110

4.  4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic Cancer.

Authors:  Donastas Sakellariou-Thompson; Marie-Andrée Forget; Caitlin Creasy; Vincent Bernard; Li Zhao; Young Uk Kim; Mark W Hurd; Naohiro Uraoka; Edwin Roger Parra; Ya'an Kang; Christopher A Bristow; Jaime Rodriguez-Canales; Jason B Fleming; Gauri Varadhachary; Milind Javle; Michael J Overman; Hector A Alvarez; Timothy P Heffernan; Jianhua Zhang; Patrick Hwu; Anirban Maitra; Cara Haymaker; Chantale Bernatchez
Journal:  Clin Cancer Res       Date:  2017-09-25       Impact factor: 12.531

Review 5.  Insights into Tumor-Associated Tertiary Lymphoid Structures: Novel Targets for Antitumor Immunity and Cancer Immunotherapy.

Authors:  Anthony B Rodriguez; Victor H Engelhard
Journal:  Cancer Immunol Res       Date:  2020-11       Impact factor: 11.151

6.  Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinoma.

Authors:  Isabel Poschke; Marta Faryna; Frank Bergmann; Michael Flossdorf; Claudia Lauenstein; Jennifer Hermes; Ulf Hinz; Thomas Hank; Roland Ehrenberg; Michael Volkmar; Martin Loewer; Hanno Glimm; Thilo Hackert; Martin R Sprick; Thomas Höfer; Andreas Trumpp; Niels Halama; Jessica C Hassel; Oliver Strobel; Markus Büchler; Ugur Sahin; Rienk Offringa
Journal:  Oncoimmunology       Date:  2016-10-07       Impact factor: 8.110

7.  Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery.

Authors:  Egesta Lopci; Luca Toschi; Fabio Grizzi; Daoud Rahal; Laura Olivari; Giovanni Francesco Castino; Silvia Marchetti; Nina Cortese; Dorina Qehajaj; Daniela Pistillo; Marco Alloisio; Massimo Roncalli; Paola Allavena; Armando Santoro; Federica Marchesi; Arturo Chiti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-06-01       Impact factor: 9.236

Review 8.  Tertiary lymphoid structures in the era of cancer immunotherapy.

Authors:  Catherine Sautès-Fridman; Florent Petitprez; Julien Calderaro; Wolf Herman Fridman
Journal:  Nat Rev Cancer       Date:  2019-06       Impact factor: 60.716

Review 9.  Tertiary Lymphoid Structures as a Predictive Biomarker of Response to Cancer Immunotherapies.

Authors:  Marta Trüb; Alfred Zippelius
Journal:  Front Immunol       Date:  2021-05-12       Impact factor: 7.561

Review 10.  Role of B Cells in Responses to Checkpoint Blockade Immunotherapy and Overall Survival of Cancer Patients.

Authors:  Sangwoo S Kim; Whitney A Sumner; Sayuri Miyauchi; Ezra E W Cohen; Joseph A Califano; Andrew B Sharabi
Journal:  Clin Cancer Res       Date:  2021-07-06       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.